Italia markets closed

Grifols, S.A. (GRF.MC)

MCE - MCE Prezzo differito. Valuta in EUR.
Aggiungi a portafoglio
21,97-0,26 (-1,17%)
Alla chiusura: 5:35PM CEST
Schermo intero
Chiusura precedente22,23
Aperto22,19
Denaro21,88 x 0
Lettera21,90 x 0
Min-Max giorno21,84 - 22,35
Intervallo di 52 settimane19,18 - 27,72
Volume568.114
Media Volume726.683
Capitalizzazione12,768B
Beta (5 anni mensile)0,10
Rapporto PE (ttm)22,67
EPS (ttm)0,97
Prossima data utili03 nov 2021 - 08 nov 2021
Rendimento e dividendo (forward)0,36 (1,66%)
Data ex dividendo03 giu 2021
Stima target 1A26,73
  • GlobeNewswire

    GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19

    First-in-human study evaluating recombinant hyperimmunes SOUTH SAN FRANCISCO, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the first patient has been dosed in its Phase 1 clinical trial of GIGA-2050, the company’s recombinant hyperimmune polyclonal antibody drug designed to provide passive immunity